Datasets:

alexcpn
/

fda-faers-parquet

primaryid string	caseid string	caseversion string	i_f_code string	event_dt string	mfr_dt string	init_fda_dt string	fda_dt string	rept_cod string	auth_num string	mfr_num string	mfr_sndr string	lit_ref string	age string	age_cod string	age_grp string	sex string	e_sub string	wt string	wt_cod string	rept_dt string	to_mfr string	occp_cod string	reporter_country string	occr_country string
228581751	22858175	1	I	20230816	20230822	20230824	20230824	EXP	null	US-ROCHE-3409974	ROCHE	null	63	YR	null	F	Y	null	null	20230824	null	CN	US	null
228581761	22858176	1	I	20230801	20230818	20230824	20230824	PER	null	US-UNITED THERAPEUTICS-UNT-2023-023867	UNITED THERAPEUTICS	null	73	YR	null	F	Y	44.898	KG	20230824	null	CN	US	US
228581771	22858177	1	I	20230801	20230821	20230824	20230824	EXP	null	DE-ABBVIE-5378826	ABBVIE	null	73	YR	null	M	Y	null	null	20230824	null	CN	DE	DE
228581781	22858178	1	I	null	20230726	20230824	20230824	EXP	null	US-SANDOZ-SDZ2023US017464	SANDOZ	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228581791	22858179	1	I	null	20230823	20230824	20230824	PER	null	US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-257194	BOEHRINGER INGELHEIM	null	86	YR	E	M	Y	null	null	20230824	null	CN	US	US
228581801	22858180	1	I	null	20230822	20230824	20230824	PER	null	US-AMGEN-USASP2023149549	AMGEN	null	null	null	null	null	Y	null	null	20230823	null	PH	US	US
228581811	22858181	1	I	null	20230814	20230824	20230824	EXP	null	US-ELI_LILLY_AND_COMPANY-US202106014676	ELI LILLY AND CO	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228581831	22858183	1	I	20230806	20230817	20230824	20230824	EXP	null	US-ELI_LILLY_AND_COMPANY-US202308011458	ELI LILLY AND CO	null	null	null	A	F	Y	null	null	20230824	null	CN	US	US
228581841	22858184	1	I	null	20230822	20230824	20230824	PER	null	US-ELI_LILLY_AND_COMPANY-US202308013950	ELI LILLY AND CO	null	null	null	null	null	Y	null	null	20230824	null	HP	US	US
228581851	22858185	1	I	null	20230818	20230824	20230824	PER	null	US-ELI_LILLY_AND_COMPANY-US202308012240	ELI LILLY AND CO	null	null	null	null	M	Y	null	null	20230824	null	CN	US	US
228581861	22858186	1	I	20230427	20230815	20230824	20230824	EXP	null	US-ELI_LILLY_AND_COMPANY-US202308011658	ELI LILLY AND CO	null	26	YR	null	F	Y	null	null	20230824	null	CN	US	US
228581871	22858187	1	I	null	20230815	20230824	20230824	EXP	null	BR-ELI_LILLY_AND_COMPANY-BR202308009768	ELI LILLY AND CO	null	null	null	null	F	Y	null	null	20230824	null	CN	BR	BR
228581881	22858188	1	I	null	20230817	20230824	20230824	EXP	null	US-ELI_LILLY_AND_COMPANY-US202308011643	ELI LILLY AND CO	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228581892	22858189	2	F	null	20230914	20230824	20230920	EXP	null	JP-ELI_LILLY_AND_COMPANY-JP202308010853	ELI LILLY AND CO	null	55	YR	null	F	Y	null	null	20230920	null	CN	JP	JP
228581901	22858190	1	I	null	20230822	20230824	20230824	PER	null	US-ELI_LILLY_AND_COMPANY-US202308013985	ELI LILLY AND CO	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228581914	22858191	4	F	20200101	20230831	20230824	20230915	EXP	null	BR-ELI_LILLY_AND_COMPANY-BR202308010659	ELI LILLY AND CO	null	null	null	null	F	Y	null	null	20230914	null	CN	BR	BR
228581921	22858192	1	I	20230817	20230817	20230824	20230824	EXP	null	US-ELI_LILLY_AND_COMPANY-US202308012561	ELI LILLY AND CO	null	80	YR	null	F	Y	null	null	20230824	null	CN	US	US
228581931	22858193	1	I	null	20230801	20230824	20230824	EXP	null	US-SANDOZ-SDZ2023US017534	SANDOZ	null	null	null	null	F	Y	104.55	KG	20230824	null	HP	US	US
228581941	22858194	1	I	null	20230822	20230824	20230824	PER	null	US-BRISTOL-MYERS SQUIBB COMPANY-2023-118929	BRISTOL MYERS SQUIBB	null	81	YR	E	F	Y	61.69	KG	20230824	null	HP	US	US
228581951	22858195	1	I	20230201	20230814	20230824	20230824	EXP	null	DE-ABBVIE-5367666	ABBVIE	null	64	YR	null	M	Y	null	null	20230824	null	CN	DE	DE
228581972	22858197	2	F	20230205	20230905	20230824	20230909	30DAY	null	EG-SANDOZ INC.-SDZ2023EG017745	SANDOZ	null	11	YR	null	M	Y	26	KG	20230909	null	CN	EG	EG
228581981	22858198	1	I	null	20230817	20230824	20230824	PER	null	US-JNJFOC-20230845906	JOHNSON AND JOHNSON	null	null	null	A	F	Y	null	null	20230824	null	HP	US	US
228581991	22858199	1	I	null	20230822	20230824	20230824	PER	null	US-ABBVIE-5379373	ABBVIE	null	null	null	null	null	Y	null	null	20230824	null	CN	US	US
228582011	22858201	1	I	null	20230810	20230824	20230824	EXP	null	CA-AUROBINDO-AUR-APL-2023-054108	AUROBINDO	null	50	YR	null	F	Y	null	null	20230824	null	MD	CA	CA
228582021	22858202	1	I	null	20230608	20230824	20230824	EXP	null	US-SANDOZ INC.-SDZ2023US017463	SANDOZ	null	null	null	null	M	Y	100	KG	20230824	null	HP	US	US
228582031	22858203	1	I	20230810	20230811	20230824	20230824	EXP	null	US-Accord-374062	ACCORD	null	65	YR	E	M	Y	null	null	20230823	null	HP	US	US
228582041	22858204	1	I	20230314	20230811	20230824	20230824	EXP	ES-AEMPS-1396339	ES-Accord-374168	ACCORD	null	60	YR	A	M	Y	null	null	20230823	null	MD	ES	ES
228582051	22858205	1	I	20160729	20230811	20230824	20230824	EXP	DE-EMA-DD-20191219-sahu_k-154547	DE-Accord-167809	ACCORD	null	67	YR	E	M	Y	67	KG	20230823	null	MD	DE	DE
228582062	22858206	2	F	20230817	20230823	20230824	20230828	EXP	null	AR-AMGEN-ARGSP2023148710	AMGEN	null	63	YR	A	M	Y	null	null	20230828	null	CN	AR	AR
228582071	22858207	1	I	null	20230813	20230824	20230824	EXP	GB-MHRA-ADR 28117266	GB-Accord-374140	ACCORD	null	22	YR	A	M	Y	null	null	20230823	null	HP	GB	GB
228582081	22858208	1	I	20210518	20230811	20230824	20230824	EXP	PL-URPL-DML-MLP.4401.1.3100.2021	PL-Accord-374147	ACCORD	null	76	YR	E	F	Y	74	KG	20230823	null	MD	PL	PL
228582091	22858209	1	I	null	20230814	20230824	20230824	EXP	null	US-AMGEN-USASP2023145883	AMGEN	Levy E.; Pfalzer L. A.. NEW LYMPHATIC CORDING AS A PRECURSOR TO DETECTION OF RECURRENT BREAST CANCER: A CASE REPORT. Rehabilitation oncology. 2016;34 (1):E11	43	YR	A	F	Y	null	null	20230823	null	HP	US	US
228582111	22858211	1	I	null	20230816	20230824	20230824	EXP	null	US-SANDOZ INC.-SDZ2023US017560	SANDOZ	null	null	null	null	M	Y	null	null	20230824	null	MD	US	US
228582121	22858212	1	I	null	20230818	20230824	20230824	EXP	null	DE-SANDOZ-SDZ2023DE017290	SANDOZ	null	null	null	null	F	Y	null	null	20230824	null	CN	DE	DE
228582131	22858213	1	I	20230526	20230811	20230824	20230824	EXP	FR-EMA-2023714-AUTODUP-1689370267402	FR-Accord-374157	ACCORD	null	96	YR	E	F	Y	97	KG	20230823	null	MD	FR	FR
228582161	22858216	1	I	null	20230822	20230824	20230824	EXP	null	US-ABBVIE-5378212	ABBVIE	null	null	null	null	M	Y	null	null	20230824	null	CN	US	US
228582171	22858217	1	I	20230707	20230814	20230824	20230824	EXP	null	PT-GLAXOSMITHKLINE-PTCH2023HLN040413	GLAXOSMITHKLINE	null	null	null	null	null	Y	null	null	20230824	null	PH	PT	PT
228582181	22858218	1	I	20230716	20230819	20230824	20230824	EXP	null	CN-GLAXOSMITHKLINE-CNCH2023APC040343	GLAXOSMITHKLINE	null	null	null	null	null	Y	null	null	20230824	null	HP	CN	CN
228582191	22858219	1	I	null	20230818	20230824	20230824	30DAY	null	US-GSK-US2023112606	GLAXOSMITHKLINE	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228582201	22858220	1	I	null	20230816	20230824	20230824	30DAY	null	US-GSK-US2023111538	GLAXOSMITHKLINE	null	80	YR	null	F	Y	null	null	20230824	null	CN	US	US
228582211	22858221	1	I	20230801	20230816	20230824	20230824	EXP	null	CN-GLAXOSMITHKLINE-CNCH2023APC040319	GLAXOSMITHKLINE	null	null	null	null	null	Y	null	null	20230824	null	HP	CN	CN
228582221	22858222	1	I	null	20230816	20230824	20230824	EXP	null	US-AMGEN-USASP2023145171	AMGEN	Rossoff J.; Elhodaky M.; Gunderman L. M. et al.. Relapse of large B-cell lymphoma with IRT4 rearrangement associated with SLAM-associated protein deficiency. Pediatric Blood + Cancer. 2023;70 (9):1-4	7	YR	C	M	Y	null	null	20230823	null	HP	US	US
228582242	22858224	2	F	null	20230829	20230824	20230901	EXP	null	US-ABBVIE-5378232	ABBVIE	null	null	null	null	F	Y	null	null	20230901	null	CN	US	US
228582251	22858225	1	I	null	20230822	20230824	20230824	EXP	null	CA-CELLTRION INC.-2023CA016646	CELLTRION	null	null	null	null	null	Y	null	null	20230824	null	MD	CA	CA
228582261	22858226	1	I	null	20230726	20230824	20230824	EXP	null	US-SANDOZ INC.-SDZ2023US017605	SANDOZ	null	null	null	null	M	Y	null	null	20230824	null	MD	US	US
228582271	22858227	1	I	20230406	20230822	20230824	20230824	EXP	null	NVSC2023US183802	NOVARTIS	null	72	YR	null	M	Y	null	null	20230824	null	CN	US	US
228582291	22858229	1	I	null	20230817	20230824	20230824	PER	null	US-JNJFOC-20230842967	JOHNSON AND JOHNSON	null	null	null	null	M	Y	null	null	20230824	null	HP	US	US
228582302	22858230	2	F	null	20230817	20230824	20230828	EXP	null	US-JNJFOC-20230839848	JOHNSON AND JOHNSON	null	4	DEC	A	null	Y	null	null	20230828	null	HP	US	US
228582311	22858231	1	I	null	20230607	20230824	20230824	EXP	null	US-SANDOZ INC.-SDZ2023US017526	SANDOZ	null	null	null	null	F	Y	93.18	KG	20230824	null	MD	US	US
228582321	22858232	1	I	null	20230817	20230824	20230824	PER	null	US-JNJFOC-20230844847	JOHNSON AND JOHNSON	null	null	null	null	M	Y	null	null	20230824	null	CN	US	US
228582331	22858233	1	I	20230101	20230821	20230824	20230824	EXP	null	US-BRISTOL-MYERS SQUIBB COMPANY-2023-117621	BRISTOL MYERS SQUIBB	null	75	YR	E	M	Y	null	null	20230824	null	HP	US	US
228582341	22858234	1	I	null	20230726	20230824	20230824	EXP	null	US-002147023-NVSC2023US126383	SANDOZ	null	null	null	null	F	Y	73	KG	20230824	null	HP	US	US
228582371	22858237	1	I	null	20230811	20230824	20230824	EXP	null	US-LEO Pharma-362129	LEO PHARM	null	60	YR	null	F	Y	null	null	20230824	null	CN	US	US
228582391	22858239	1	I	null	20230815	20230824	20230824	EXP	null	US-INTERCEPT-PM2023001503	INTERCEPT PHARMACEUTICALS	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228582412	22858241	2	F	20230821	20230824	20230824	20230828	PER	null	US-AMGEN-USASP2023148342	AMGEN	null	null	null	null	null	Y	null	null	20230828	null	PH	US	US
228582432	22858243	2	F	20230818	20230908	20230824	20230913	PER	null	US-AMGEN-USASP2023149452	AMGEN	null	71	YR	E	M	Y	null	null	20230913	null	CN	US	US
228582441	22858244	1	I	20230628	20230811	20230824	20230824	EXP	null	US-ROCHE-3374567	ROCHE	null	76	YR	null	F	Y	null	null	20230824	null	HP	US	null
228582461	22858246	1	I	null	20230717	20230824	20230824	EXP	null	AR-SANDOZ-SDZ2023AR017446	SANDOZ	null	null	null	null	M	Y	null	null	20230824	null	CN	AR	AR
228582471	22858247	1	I	20230722	20230815	20230824	20230824	EXP	null	CN-SANDOZ-SDZ2023CN017005	SANDOZ	null	76	YR	null	M	Y	60	KG	20230824	null	HP	CN	CN
228582491	22858249	1	I	null	20230817	20230824	20230824	30DAY	null	US-GSK-US2023112656	GLAXOSMITHKLINE	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228582511	22858251	1	I	null	20230815	20230824	20230824	EXP	null	GB-HETERO-AMR2023GB02372	HETERO	null	58	YR	null	F	Y	126	KG	20230824	null	CN	GB	GB
228582522	22858252	2	F	20210101	20230823	20230824	20230825	EXP	null	US-ABBVIE-5379333	ABBVIE	null	38	YR	null	M	Y	112	KG	20230825	null	MD	US	FR
228582531	22858253	1	I	null	20230822	20230824	20230824	EXP	null	GB-SANDOZ-SDZ2023GB017367	SANDOZ	null	null	null	null	F	Y	null	null	20230824	null	HP	GB	GB
228582541	22858254	1	I	null	20230817	20230824	20230824	PER	null	US-JNJFOC-20230842304	JOHNSON AND JOHNSON	null	null	null	A	F	Y	null	null	20230824	null	MD	US	US
228582561	22858256	1	I	null	20230819	20230824	20230824	EXP	null	US-JAZZ PHARMACEUTICALS-2023-US-017723	JAZZ	null	16	YR	null	M	Y	null	null	20230824	null	CN	US	US
228582571	22858257	1	I	null	20230821	20230824	20230824	PER	null	US-AMGEN-USASP2023148003	AMGEN	null	null	null	null	F	Y	null	null	20230823	null	CN	US	US
228582591	22858259	1	I	20230601	20230818	20230824	20230824	PER	null	US-ABBVIE-5375189	ABBVIE	null	38	YR	null	M	Y	122	KG	20230824	null	CN	US	US
228582601	22858260	1	I	null	20230531	20230824	20230824	EXP	null	US-SANDOZ INC.-SDZ2023US017508	SANDOZ	null	null	null	null	M	Y	113.39	KG	20230824	null	MD	US	US
228582611	22858261	1	I	null	20230607	20230824	20230824	EXP	null	US-SANDOZ-SDZ2023US017500	SANDOZ	null	null	null	null	F	Y	null	null	20230824	null	MD	US	US
228582621	22858262	1	I	null	20230817	20230824	20230824	EXP	null	FR-BRISTOL-MYERS SQUIBB COMPANY-2023-117743	BRISTOL MYERS SQUIBB	null	null	null	null	null	Y	null	null	20230824	null	MD	FR	FR
228582631	22858263	1	I	null	20230726	20230824	20230824	EXP	null	US-SANDOZ INC.-SDZ2023US017442	SANDOZ	null	null	null	null	M	Y	null	null	20230824	null	MD	US	US
228582641	22858264	1	I	null	20230822	20230824	20230824	EXP	null	NVSC2023US183580	NOVARTIS	null	null	null	null	F	Y	null	null	20230824	null	CN	US	US
228582651	22858265	1	I	null	20230821	20230824	20230824	PER	null	US-TAKEDA-2023TUS081829	TAKEDA	null	null	null	null	F	Y	84	KG	20230824	null	MD	US	US
228582671	22858267	1	I	null	20230822	20230824	20230824	PER	null	US-AMGEN-USASP2023148850	AMGEN	null	null	null	null	F	Y	null	null	20230823	null	CN	US	US
228582681	22858268	1	I	null	20230726	20230824	20230824	EXP	null	US-SANDOZ-SDZ2023US017484	SANDOZ	null	null	null	null	F	Y	null	null	20230824	null	MD	US	US
228582692	22858269	2	F	null	20230728	20230824	20230907	30DAY	null	US-GSK-US2023112671	GLAXOSMITHKLINE	null	null	null	null	F	Y	null	null	20230907	null	CN	US	US
228582701	22858270	1	I	20230101	20230814	20230824	20230824	30DAY	null	US-GSK-US2023AMR110853	GLAXOSMITHKLINE	null	null	null	null	M	Y	null	null	20230824	null	CN	US	US
228582712	22858271	2	F	20230511	20230829	20230824	20230901	EXP	null	JP-GSK-JP2023040960	GLAXOSMITHKLINE	null	null	null	null	null	Y	null	null	20230901	null	MD	JP	JP
228582721	22858272	1	I	20230711	20230818	20230824	20230824	30DAY	null	US-GSK-US2023112624	GLAXOSMITHKLINE	null	71	YR	null	M	Y	null	null	20230824	null	CN	US	US
228582731	22858273	1	I	null	20230822	20230824	20230824	PER	null	US-GLAXOSMITHKLINE-USCH2023040720	GLAXOSMITHKLINE	null	67	YR	null	F	Y	null	null	20230824	null	CN	US	US
228582741	22858274	1	I	20230806	20230814	20230824	20230824	EXP	null	CO-BAXTER-2023BAX028709	BAXTER	null	65	YR	null	F	Y	null	null	20230824	null	HP	CO	CO
228582751	22858275	1	I	20230625	20230821	20230824	20230824	EXP	FR-AFSSAPS-CN2023000744	FR-BRISTOL-MYERS SQUIBB COMPANY-2023-117554	BRISTOL MYERS SQUIBB	null	78	YR	E	M	Y	58	KG	20230824	null	MD	FR	FR
228582761	22858276	1	I	null	20230822	20230824	20230824	PER	null	US-ABBVIE-5379631	ABBVIE	null	null	null	null	F	Y	null	null	20230824	null	MD	US	US
228582771	22858277	1	I	null	20230817	20230824	20230824	EXP	null	CA-BAXTER-2023BAX028926	BAXTER	null	null	null	null	F	Y	null	null	20230824	null	MD	CA	CA
228582791	22858279	1	I	null	20230620	20230824	20230824	EXP	null	US-SANDOZ-SDZ2023US017512	SANDOZ	null	null	null	null	F	Y	90.71	KG	20230824	null	MD	US	US
228582801	22858280	1	I	null	20230818	20230824	20230824	EXP	null	US-002147023-NVSC2023US140120	SANDOZ	null	null	null	null	F	Y	72.562	KG	20230824	null	MD	US	US
228582811	22858281	1	I	null	20230822	20230824	20230824	PER	null	US-ABBVIE-5379454	ABBVIE	null	20	YR	null	M	Y	null	null	20230824	null	MD	US	US
228582821	22858282	1	I	20200818	20230818	20230824	20230824	EXP	null	US-ROCHE-3408753	ROCHE	null	null	null	null	null	Y	null	null	20230824	null	MD	US	null
228582831	22858283	1	I	null	20230821	20230824	20230824	PER	null	US-AMGEN-USASP2023149394	AMGEN	null	null	null	null	null	Y	null	null	20230823	null	CN	US	US
228582841	22858284	1	I	null	20230717	20230824	20230824	EXP	null	CA-SANDOZ-SDZ2023CA017545	SANDOZ	null	null	null	null	M	Y	null	null	20230824	null	MD	CA	CA
228582851	22858285	1	I	null	20230726	20230824	20230824	EXP	null	US-SANDOZ INC.-SDZ2023US017185	SANDOZ	null	null	null	null	F	Y	69.09	KG	20230824	null	HP	US	US
228582861	22858286	1	I	null	20230811	20230824	20230824	EXP	null	US-MALLINCKRODT-MNK202303788	MALLINCKRODT	null	null	null	E	F	Y	null	null	20230824	null	CN	US	US
228582871	22858287	1	I	null	20230817	20230824	20230824	EXP	null	CA-SANDOZ-SDZ2023CA017052	SANDOZ	null	null	null	E	M	Y	null	null	20230824	null	CN	CA	CA
228582881	22858288	1	I	20230406	20230810	20230824	20230824	EXP	FR-AFSSAPS-MP2023000862	FR-drreddys-SPO/FRA/23/0174959	DR REDDYS	null	79	YR	E	M	Y	72	KG	20230824	null	MD	FR	FR
228582891	22858289	1	I	20230320	20230810	20230824	20230824	EXP	FR-AFSSAPS-PC2023000409	FR-drreddys-SPO/FRA/23/0174967	DR REDDYS	null	73	YR	E	M	Y	71	KG	20230824	null	HP	FR	FR
228582901	22858290	1	I	20230802	20230818	20230824	20230824	EXP	null	US-ABBVIE-5378026	ABBVIE	null	null	null	I	null	Y	null	null	20230824	null	HP	US	US
228582911	22858291	1	I	20161026	20230505	20230824	20230824	EXP	null	US-ENDO PHARMACEUTICALS INC-2023-001936	ENDO	null	null	null	null	null	Y	null	null	20230824	null	CN	US	US
228582931	22858293	1	I	null	20230818	20230824	20230824	EXP	null	CL-002147023-NVSC2023CL132902	SANDOZ	null	16	YR	null	M	Y	45	KG	20230824	null	CN	CL	CL
228582951	22858295	1	I	null	20230816	20230824	20230824	EXP	null	US-NOVITIUMPHARMA-2023USNVP01387	NOVITIUM PHARMA	Abdullahi Sulaiman.DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AS A CAUSE OF IGA NEPHROPATHY.American Journal of Kidney Diseases.01-APR-2023;81(4):S9-S10	71	YR	E	F	Y	null	null	20230824	null	HP	US	US
228582961	22858296	1	I	20230101	20230821	20230824	20230824	PER	null	US-JNJFOC-20230850702	JOHNSON AND JOHNSON	null	20	YR	A	F	Y	null	null	20230824	null	MD	US	US

End of preview. Expand in Data Studio

FDA FAERS Adverse Event Reports

Pre-processed FDA Adverse Event Reporting System (FAERS) data in Parquet format for pharmacovigilance signal detection.

Tables

Table	Description
DEMO	Demographics and case admin (deduplicated: latest CASEVERSION per CASEID)
DRUG	Drug/medication info (drugname, prod_ai, role_cod, route, dose)
REAC	Adverse reactions (MedDRA preferred terms)
OUTC	Patient outcomes (death, hospitalization, disability, etc.)
RPSR	Report sources
THER	Therapy dates
INDI	Indications for use

All tables linked by primaryid. Drug role codes: PS=Primary Suspect, SS=Secondary Suspect, C=Concomitant, I=Interacting.

Current Coverage

2024 Q4 (410,849 unique cases)

Usage with DuckDB

import duckdb
conn = duckdb.connect()
conn.install_extension("httpfs")
conn.load_extension("httpfs")

demo = conn.execute("""
    SELECT COUNT(*) as total_cases
    FROM read_parquet("hf://datasets/alexcpn/fda-faers-parquet/data/DEMO.parquet")
""").fetchdf()

Disclaimer

FAERS is a voluntary reporting system. Report counts do not establish causation. Disproportionality signals (PRR, ROR) indicate statistical associations that require clinical validation. Not intended for direct clinical decision-making.

Source

FDA FAERS Quarterly Data Extract Files

Downloads last month: 129